BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy - sprookjes - yvandenbroek - TriplyDB

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

http://www.wikidata.org/entity/Q28207909

about

sameAs

Adenosine receptors as therapeutic targets Adenosine receptors and asthma in humans Acute decompensated heart failure: contemporary medical management Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies)Adenosine receptors and the kidney Effects of the adenosine A1 receptor inhibitor FK 838 on proximal tubular fluid output in rats Renal effects of the novel selective adenosine A1 receptor blocker SLV329 in experimental liver cirrhosis in rats The impact of coffee consumption on blood pressure, cardiovascular disease and diabetes mellitus.Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.Glomerular tubular balance is suppressed in adenosine type 1 receptor-deficient mice.Therapeutic options for the management of the cardiorenal syndrome.The cardiorenal syndrome: a review Cardiorenal syndrome in acute heart failure syndromes.Ultrafiltration versus intravenous diuretic therapy to treat acute heart failure: a systematic review.Adenosine type 1 receptor antagonists in fluid retaining disorders.Determinants of the creatinine clearance to glomerular filtration rate ratio in patients with chronic kidney disease: a cross-sectional study.Adenosine and kidney function: potential implications in patients with heart failure.Novel pharmacological treatments for heart failure.Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure.Adenosine and protection from acute kidney injury.Recent advances in natriuretic peptides in congestive heart failure.BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.Introduction to adenosine receptors as therapeutic targets.Predictors of emergency department observation unit outcomes.The benefits of early vasoactive therapy in the treatment of acute decompensated heart failure.Continuous renal replacement therapy versus furosemide for management of kidney impairment in heart transplant recipients with volume overload Emerging drugs for acute and chronic heart failure: current and future developments.Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials.Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].V2 receptor antagonism with tolvaptan in heart failure.Overview of emerging pharmacologic agents for acute heart failure syndromes.Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches Cardiorenal syndrome: A literature review.Cardiorenal syndrome in heart failure: a cardiologist's perspective.Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.Vasodilators in the treatment of acute heart failure: what we know, what we don't.Modern approach to the treatment of decompensated heart failure.

P2860

Q24632095-8830A273-521A-4FF9-AD73-A2323638C506 Q24644125-77865499-4F67-4EB5-AB9E-948D91BEC4EF Q24650932-722A94C2-50EE-452C-995E-AE5D927056E7 Q26745670-03CD5626-CE61-438A-B450-829A7FF9FCEC Q28253255-3D494310-CABB-4460-9796-25A85D7B126B Q28570311-9189A4E6-7A90-4091-9134-FA134CE31177 Q28742066-FEBFFB7C-A376-4D49-977E-320F0F3E79B8 Q30238756-0FE85C87-7A4E-4B7F-B7C4-23E1EDFE86F9 Q34305164-60646ACB-F340-4926-81D4-E409ED7224FE Q34305475-9DCAA92B-E143-4C96-B0E3-548B103CAD7A Q34442587-EACD4558-8178-4A86-809A-E13530A95026 Q34495307-88BFA2D1-F949-442A-ACD3-3DE3DAE22052 Q34665867-183E334E-3509-42B9-9A32-F861ED2A8B07 Q34784226-25F73A7B-DB54-46EC-A1A1-D7492DED04BC Q35001005-B7B760C7-9BDD-4CD2-A0A8-34F57CF4BE82 Q35059097-AE837FAF-C099-4404-A729-ABC96DA8695C Q35151913-12766B47-7180-41B4-9972-21E6240F8D5B Q35570949-E4EEBFF3-9456-45E2-AA2F-D29ED32053C9 Q35580130-7CFA2201-4228-4058-9A75-BC6A23622CB9 Q35755490-0116D072-B3CB-432C-972C-F4D98F19C0A0 Q35790792-F008C3AA-4AA4-488C-99A3-E96791ED3A40 Q35987052-C49DF267-8247-49EC-8A2D-03914355040B Q36153376-E2225FDC-5444-4B35-A9A4-75987DD51E36 Q36248577-0DE94AB0-4955-408C-9F0F-D5E5D22E3097 Q36266387-FC1D50DE-FB00-4DB5-8539-49103BA0848C Q36599729-62E70D74-D68A-4284-99E7-83B296F5D415 Q36758585-4BB72C6E-ED8C-4E00-B623-CA61F7E08053 Q36799331-3D3EED33-5376-41C2-8877-80F7539A5FD5 Q36811824-EB4DC9D0-BF74-4E28-8C91-F4CF76809129 Q36962261-9C12B05C-81C1-43BF-8773-C8004F29FB2E Q36964715-5E7CF2E3-D569-4CC4-9876-C87D1F49DAD7 Q37086309-A766FCB9-F1D1-4DB2-89F6-5A3EBF67380B Q37108078-286FFACC-D02D-4D3A-8668-DF40C87FEC0A Q37140940-D3CD1991-90DB-4B69-A72E-8AAA8138B127 Q37145749-F52C9AD4-6DE6-4231-90A1-28B49578F2BE Q37217357-C7644882-E7F6-4028-A3CE-4D65664BFFFA Q37343008-70CF6F5E-110D-4A0A-9081-E0DFC3708447 Q37352407-9FD6A77A-8704-4DB3-9178-EAC7C7E35E3C Q37355110-F1A79985-F7EC-4E1E-B00C-8F459764DCC1 Q37390754-8631D33C-8DA9-4CDF-8DBF-7F0C396440FB

P2860

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

http://www.wikidata.org/entity/Q28207909

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@ast

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@en

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@nl

type

label

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@ast

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@en

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@nl

prefLabel

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@ast

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@en

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@nl

P1433

Q28207909-6CADF37D-E0AB-4E72-B0C0-7DC1C9FD8687

P1476

Q28207909-2C99C2B4-A14A-4ADF-8ECC-1D47DA1B71BB

P2093

Q28207909-0EDE45FD-2319-4126-893B-ECC30F9BDCB4

Q28207909-4CCB963A-1741-416B-BA8E-68C7FFCC23EE

Q28207909-5342750C-8868-4952-929A-7DFA02E278E1

Q28207909-53743AC4-5978-418C-B37A-4BCD3985121A

Q28207909-5757A106-08FB-4312-B05D-9CC4583ABF6D

Q28207909-691D33C5-A32A-41A0-B53D-8ADBF67ABC5C

Q28207909-6B9C1C2C-A5A2-4B81-9D0A-3A6A499BF28C

Q28207909-ABECA79C-1F37-4450-B8BB-79224663D50B

Q28207909-AF3C8C5F-86ED-4369-AE85-38B02C970EA6

Q28207909-DC531167-922B-4029-9286-570B01B79385

P304

Q28207909-A5105FC3-028E-40FA-9B2A-7BD919241C60

P31

Q28207909-A004643C-DAF1-4C9E-B585-8E3FFB8230F8

P3181

Q28207909-E948BB3B-ADD1-4177-8656-B148DFD2299B

P356

Q28207909-B3509397-032D-4543-A41C-4B71067058EE

P407

Q28207909-3081E8F2-FBB5-4DD2-9D13-62F81997DFE2

P433

Q28207909-3BA601ED-5707-44BD-B125-A826C1EA0E0C

P478

Q28207909-0BCAFE7B-4162-441C-8393-79C6D57EB03C

P577

Q28207909-56A16392-F080-43AE-BB72-E76974C5843B

P5875

Q28207909-A5444231-BD00-453B-9F89-3F3DFC013980

P698

Q28207909-42F96A8C-5A0D-4AAC-B9C6-7CF9EE71EA69

P3181

P356

P1433

P1476

BG9719 (CVT-124), an A1 adenos ...... observed with diuretic therapy

@en

P2093

Barry Ticho

http://www.w3.org/2001/XMLSchema#string

D Craig Brater

http://www.w3.org/2001/XMLSchema#string

Donald Bennett

http://www.w3.org/2001/XMLSchema#string

Edward Havranek

http://www.w3.org/2001/XMLSchema#string

Evan Beckman

http://www.w3.org/2001/XMLSchema#string

Farere Dyer

http://www.w3.org/2001/XMLSchema#string

Ignatius Thomas

http://www.w3.org/2001/XMLSchema#string

Miguel Gomez

http://www.w3.org/2001/XMLSchema#string

Robert Bourge

http://www.w3.org/2001/XMLSchema#string

Stephen S Gottlieb

http://www.w3.org/2001/XMLSchema#string

P304

1348-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1232263

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/HC1102.105264

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277495723

http://www.w3.org/2001/XMLSchema#string

P698

11901047

http://www.w3.org/2001/XMLSchema#string